21 August 2020 : Clinical Research
Retrospective Analysis of Clinical Outcomes in Patients with Immunoglobulin A Nephropathy and Persistent Hematuria Following Renin-Angiotensin System Blockade
Jingjing Chen12ACE, Shao Liu1ADE, Hui Xu23AF*, Wei Wang3BC, Yanyun Xie3B, Wenbin Tang3B, Qiongjing Yuan3B, Li Zheng4D, Lizhen Lin35F, Shuangshuang Fu6F, Jinmei Shen7CDOI: 10.12659/MSM.922839
Med Sci Monit 2020; 26:e922839
Table 2 Outcomes of treated and untreated IgAN patients only with persistent hematuria initially (n=110).
| Outcomes | All | Treatment group | Untreated group | P |
|---|---|---|---|---|
| Primary outcome (n, %)* | 38 (34.5) | 8 (18.2) | 30 (45.5) | 0.003 |
| Final eGFR (ml/min/1.73 m) | 107.1±24.2 | 106.0±22.1 | 107.8±25.6 | 0.71 |
| Hematuria change from start to end of follow-up (cells/hpf)** | 35.0±102.1 | 48.7±110.0 | 25.9±96.2 | 0.01/0.03# |
| Final hematuria (cells/hpf) | 4.5 (1.7–19.2) | 3.6 (1.7–6.2) | 5.9 (1.7–29.3) | 0.049 |
| Decreased percentage of hematuria (%) | 82 (21–94) | 90 (72–96) | 72 (6–91) | 0.01 |
| Rate of eGFR decline (ml/min per 1.73 m/y) | 0.51 (−3.98–5.35) | 1.04 (−1.66–4.41) | −0.05 (−4.73–5.58) | 0.38 |
| Final systolic pressure (mmHg) | 115 (110–122) | 118 (110–125) | 115 (107–121) | 0.38 |
| Final diastolic pressure (mmHg) | 75 (65–81) | 76 (74–85) | 69 (63–80) | 0.17 |
| Follow-up time (for the primary outcome, months) | 18.0 (10.5–30.0) | 21 (12.0–34.5) | 16.5 (8.0–27.0) | 0.11 |
| Follow-up time (for the whole follow-up periods, months)## | 24.0 (12.8–36.3) | 24.5 (12.5–38.0) | 24.0 (12.8–32.0) | 0.28 |
| * Appearance of proteinuria; ** initial hematuria – final hematuria; # paired test; ## all patients were followed up until June 2019 whether progressed to the primary endpoint or not. eGFR – estimated glomerular filtration rate. | ||||